GUIDEWIRE
23.3.2022 07:02:05 CET | Business Wire | Press release
Guidewire (NYSE: GWRE) today announced that it has opened its new EMEA headquarters 10 years after the company opened its first office in Dublin. Based in Blanchardstown, the new office building occupies 85,000ft² and is evidence of Guidewire’s continued commitment to Ireland and its customers across Europe. Adapting to the new world of work, Guidewire is offering employees fully remote and hyperflexible working practices. As well as providing employees with a state-of-the-art work environment, the office also includes an executive briefing centre for its customer and partner community across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006033/en/
Since 2011, Guidewire’s Dublin base has grown to become the company’s largest employee community in Europe and outside of the USA, including a diverse range of 35+ nationalities. Guidewire anticipates scaling headcount by about 150 new recruits to around 600 staff over the next two to three years and is actively hiring across a range of positions, from entry-level graduate roles to business analysts, cloud operations, consulting managers, engineering, HR & Recruitment, project managers, specialist cloud transition roles, and technology consultants.
Since 2016 Guidewire Dublin has made the top 20 in the Great Place to Work, including 10th place in Ireland’s Best Workplaces 2021 for best large company.
“This is an exciting moment for Guidewire in Ireland as we open our new EMEA HQ, reflecting the enormous contribution of our team to the Guidewire corporate and customer community,” said Niall Lalor, Ireland country manager, Guidewire. “As the company has grown and evolved over the past 10 years in Ireland, I’m hugely proud that we have retained our strong sense of identity and close-knit culture throughout. We’ve still only scratched the surface and look forward to growing our talented team even more across the country, with Guidewire in Dublin well placed as a hub for innovation that supports our business both in EMEA and globally.”
The Irish operations include Customer & Cloud Operations, Delivery Services, and Product Development, with teams that have spearheaded Guidewire’s digital products, created specific local solutions for European customers, as well as managed the implementations and support of the company’s first cloud customers. The siting of the cloud team in Dublin also takes advantage of access to top new graduates from Ireland, the wider European Union, and beyond.
“Ireland has been central to Guidewire’s international growth over the past 10 years,” said Mike Rosenbaum, chief executive officer, Guidewire. “It’s nothing new to say that the world has witnessed extraordinary changes over the past two years and the insurance industry is no exception. Guidewire continues to be an indispensable partner to our 450+ customers around the world. Guidewire aspires to design, build, and run a mission critical cloud service, and our team in Ireland is critical to making this a reality.”
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, said “I’m so pleased Guidewire has chosen Blanchardstown for its new EMEA headquarters. Guidewire is a leading player in the software industry and this expansion, which will create an additional 150 highly skilled jobs, demonstrates the company’s continued commitment to Ireland after 10 years. I wish the team every success with their expansion plans.”
Commenting on the news Mary Buckley, Executive Director, IDA Ireland, said “Today’s announcement demonstrates Guidewire’s continued confidence in the availability of a highly skilled and talented workforce in Ireland to further support its evolution and to deliver on its strategic corporate goals. I wish the team continued success in their new office building and offer the company the ongoing support of IDA Ireland.”
Further details are available at: https://careers.guidewire.com/location/dublin
Dublin office video:
https://players.brightcove.net/929656735001/41G8Cuaute_default/index.html?videoId=6300984518001
About Guidewire
Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 450 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localisation, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
